Event-Driven Stocks

BioRestorative Therapies, Inc.

BRTXNasdaq

Healthcare · Services-Misc Health & Allied Services, NEC · NV · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$359,700$401,000$145,800$119,800$46,000$77,000
Operating income−$15.6M−$11.6M−$15.2M−$19.0M−$26.3M−$2.8M
Net income−$14.2M−$9.0M−$10.4M−$18.5M−$44.3M−$11.3M
Total assets$4.1M$12.3M$12.6M$16.4M$22.5M$4.3M
Total liabilities—$3.7M$2.6M$602,619$856,497$5.7M
Equity$356,744$8.5M$10.0M$10.3M$21.6M−$1.3M
EPS (diluted)$-1.58$-1.16$-2.47$-5.11$-37.30—
Shares out.7.5M6.8M3.8M3.6M3.18B715,544

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−4350.1%
Net margin
−3959.4%
Return on equity
−3992.2%
Return on assets
−349.1%
Return on capital (ROCE)
−4386.1%
Liabilities / assets
—
Debt / equity
—
Book value / share
$0.05
Revenue growth (YoY)
−10.3%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−84.6%clean
Piotroski F-Score
2/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
37
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 4 warning● 1 good
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
2 acquisitions0 disposalsnet +27,344 shares · last 2
InsiderDateTypeSharesPrice
Silva FranciscoOfficer — VP of Research and DevelopmentOct 6, 2025Grant11,719$1.60
Alstodt LanceOfficer — President, CEO, COBOct 6, 2025Grant15,625$1.60

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026368,6651.0-42.8%
Apr 30, 2026644,8701.0-0.3%
Apr 15, 2026647,1051.0-27.4%
Mar 31, 2026890,9081.0-32.4%
Mar 13, 20261.3M1.0+67.5%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.